Andrea Necchi, MD

Andrea Necchi, MD, shared SunRISe-4 primary results demonstrating higher pathologic response and relapse-free survival rates with TAR-200 plus sacituzumab compared with checkpoint inhibitor monotherapy, with no new safety signals observed.